期刊文献+

AFP时间分辨荧光免疫分析试剂盒的研制及其临床应用 被引量:6

Preparation of a Time-Resolved Fluoroimmunoassay kit for AFP Detection in This Laboratory and Its Clinical Application
下载PDF
导出
摘要 目的:研制AFP时间分辨荧光免疫分析(TrFIA)试剂盒。方法:采用双抗体夹心法建立AFP-Tr-FIA试剂盒,对反应条件进行优化,并对试剂盒的各项指标进行评价。结果:抗体包被浓度确定为5μg/m l,铕标抗体最佳稀释比为1 50。试剂盒的线性范围为1ng/m l^1210ng/m l,灵敏度为0.41ng/m l,准确度高,批内和批间变异系数分别5.1%~8.8%,6.7%~11.9%。与CA199、CA125、CEA和白蛋白无交叉反应。破坏试验表明试剂在37℃可稳定7d。收集50例肝癌患者和370例健康人血清,用本试剂盒测得肝癌患者血清AFP浓度(557.3ng/m l±322.1ng/m l)显著高于健康人(6.5ng/m l±5.4ng/m l)(P<0.001)。370例正常人血清标本测试该试剂盒的正常参考范围为(0~12.0)ng/m l。本试剂盒检测结果与商用W allac AFP试剂盒检测结果相关系数为0.9988。结论:试剂盒各项指标达到规定的要求,可用于临床血清AFP检测。 Objective To prepare a time - resolved fluoroimmunoassay (TrFIA) kit for detecting AFP in clinical use. Methods A double antibody sandwich TrFIA kit for AFP detection was developed in our laboratory using monoclonal antibody of anti - AFP. Results This AFP - TrFIA kit was capable of detecting AFP within the range of 1 ~1210ng/ml with the sensitivity of O. 41ng/ml and without cross - reactivity with CA199, CA125, CEA, or albumin. The intra - and inter - assay coefficients of variation were 5.1%~ 8.8% and 6.7 % ~11.9%, respectively. The prepared AFP - TrFIA reagent was stable at 37℃ for 7 days. Serum samples were collected from 50 patients with proven hepatocellular carcinoma and 370 controls. Serum AFP levels were significantly higher in the patients than those in controls (557.3ng/ml± 322. lng/ml vs 6.5ng/ml ±5.4ng/ml, P 〈0. 001 ). The correlation coefficient of the detection results between this kit and the commercially available Wailac kit for 100 blood samples was 0. 9988. Conclusion The prepared TrFIA kit for AFP detection meets the demand of clinical application with good sensitivity, precision, specificity and accuracy.
出处 《放射免疫学杂志》 CAS 2006年第4期329-332,共4页 Journal of Radioimmanology
基金 国家自然科学基金资助项目(30470497) 上海市科委重点基金资助项目(02DJ04137)
关键词 甲胎蛋白 肝癌 时间分辨荧光免疫分析 α- fetoprotein, hepatocellular carcinoma, time - resolved fluoroimmunoassay
  • 相关文献

参考文献4

  • 1Takea K.α-fetoprotein:reevaluation in hepatology.Hepotology.1990,12:1420.
  • 2Kimura H,Liu S,Yamada S,et al.Rapid increase in serum lipid peroxide 4-hydroxynonenal (HNE) through monocyte NADPH oxidase in early endo-toxemia.Free Radic Res.2005,39(8):845.
  • 3Nevalainen TJ,Eerola LI,et al.Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum.Biochim Biophys Acta.2005,1733(2~3):210.
  • 4Nomura F,Ohnishi K,Tanabe Y,et al.Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels.Cancer.1989,64:1700.

同被引文献53

  • 1盛世乐,黄钢.VEGF上调survivin和bcl-2表达及抑制乳腺癌细胞凋亡的机制探讨[J].肿瘤,2005,25(6):525-529. 被引量:17
  • 2盛世乐,韩源,覃文新,黄钢.靶向VEGF基因siRNA对放射性核素杀伤肿瘤的增强作用[J].上海第二医科大学学报,2005,25(12):1229-1234. 被引量:2
  • 3盛世乐,鲍时华,黄钢,朱翠英,袁济民.VEGF-TrFIA及其在结直肠癌中的应用[J].放射免疫学杂志,2006,19(5):435-438. 被引量:4
  • 4Pie JR,Uversky VN. Structure and function f etopro-tein: abiophysical overview[J]. Biochem Biophys Acta, 2000, 1480(1-2) :41.
  • 5Elve GI. Alpha-fetoprotin as a marker of embryo differen tiation in a normal and human tissues [J]. Transplant Rev, 1974,20:3.
  • 6Wright LM,Kreikemeier JT, Fimmel CJ. Aeoneise review of serum markers for hepatoeellular eaneer[J]. Cancer Detect Prey,2007,31(1) :35.
  • 7pie J R,Uversky V N.Structure and function f etopro-rein:ablophysical overview[J].Biochem Biophys Acta,2000,1480(1-2):41.
  • 8elve G I.Alpha-fetoprotin as a marker of embryo differen tiation in a normal and human tissues[J].Transplant Rev,1974,20:3.
  • 9Wright L M,Kreikemeier J T,Fimmel C J.Aconcise review of serum markers for hepatocellular caneer[J].Cancer Detect Ptev,2007,31(1):35.
  • 10元雄良治.肿瘤标志物在癌诊断的灵敏度及特异度[J].日本临床,1996,54(6):121-125.

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部